Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2017

  • ID: 4426901
  • Report
  • 108 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BioLingus AG
  • Daiichi Sankyo Co Ltd
  • iCo Therapeutics Inc.
  • Laboratorios LETI SL
  • ManRos Therapeutics
  • Merck & Co Inc
  • MORE
Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2017, provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape.

Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 2, 12, 9 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 1, 12 and 10 molecules, respectively.

Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BioLingus AG
  • Daiichi Sankyo Co Ltd
  • iCo Therapeutics Inc.
  • Laboratorios LETI SL
  • ManRos Therapeutics
  • Merck & Co Inc
  • MORE
Introduction

Leishmaniasis (Kala-Azar) - Overview

Leishmaniasis (Kala-Azar) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Leishmaniasis (Kala-Azar) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development

BioLingus AG

Daiichi Sankyo Co Ltd

iCo Therapeutics Inc.

Laboratorios LETI SL

ManRos Therapeutics

Matinas BioPharma Holdings Inc

Merck & Co Inc

Mologen AG

Nanomerics Ltd

Novartis AG

Oblita Therapeutics BVBA

Sequella Inc

Leishmaniasis (Kala-Azar) - Drug Profiles

(gentamicin sulfate + paromomycin sulfate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amphotericin B sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

candicidin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDRI-99288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CpGD-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-121 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DI-4G - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNDI-6148 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNF-6702 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hypoestoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon gamma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KVH-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGN-1331 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-2002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPC-1161B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-MAPA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-015-2344 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 1 for Visceral Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Trypanosomiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Visceral Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Visceral Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LHR1 for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MmpL3 for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Nucleoside Hydrolase for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Leishmaniasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

visceral leishmaniasis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leishmaniasis (Kala-Azar) - Dormant Projects

Leishmaniasis (Kala-Azar) - Discontinued Products

Leishmaniasis (Kala-Azar) - Product Development Milestones

Featured News & Press Releases

Nov 01, 2017: MOLOGEN: Grant of US$ 2.6 million for further development of vaccine

Nov 28, 2016: iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program

Aug 08, 2016: A single compound could treat three parasitic diseases

Dec 15, 2015: U.S. Issues Patent on Corifungin

Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program

Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions

Nov 03, 2014: Presentation of DNA vaccine against leishmaniasis at IMED 2014

Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients

Feb 26, 2013: National Institutes of Health Supports Acea’s Research

Jun 26, 2012: Leishdnavax Consortium Successfully Concludes Preclinical Development Of MGN1331 DNA Vaccine Against Leishmaniasis

Mar 06, 2012: £10 million boost for neglected tropical disease research at Dundee

Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis

Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS

Jul 01, 2011: FDA issues orphan-drug designation to Corifungin

Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by Laboratorios LETI SL, H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings Inc, H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by Merck & Co Inc, H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by Mologen AG, H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by Novartis AG, H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by Oblita Therapeutics BVBA, H2 2017

Leishmaniasis (Kala-Azar) - Pipeline by Sequella Inc, H2 2017

Leishmaniasis (Kala-Azar) - Dormant Projects, H2 2017

Leishmaniasis (Kala-Azar) - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BioLingus AG
  • Daiichi Sankyo Co Ltd
  • iCo Therapeutics Inc.
  • Laboratorios LETI SL
  • ManRos Therapeutics
  • Matinas BioPharma Holdings Inc
  • Merck & Co Inc
  • Mologen AG
  • Nanomerics Ltd
  • Novartis AG
  • Oblita Therapeutics BVBA
  • Sequella Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll